A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

This study is testing a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least 2 prior treatments. The drug targets a pathway that helps cancer cells survive, and researchers want to find the right dose and see how well it works. **You may be eligible if...** - You are 18 or older with confirmed B-cell or T-cell lymphoma - Your lymphoma has returned or not responded to at least 2 prior treatment regimens - No standard treatments are available or appropriate for you - Your overall health is adequate for treatment **You may NOT be eligible if...** - You have untreated brain lymphoma - You have serious heart or organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.